Mechanism of Action of Apremilast (Otezla)
Introduction Apremilast (Otezla) is an oral phosphodiesterase-4 (PDE4) inhibitor approved for psoriasis, psoriatic arthritis, and Behçet’s disease‑associated oral ulcers. By modulating intracellular signaling, it reduces inflammation and disease symptoms through balanced cytokine regulation. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral (delayed-release tablet) Bioavailability ~73% Time to Peak (Tmax) ~2–4 hours Protein Binding … Read more